Marker Therapeutics Inc (MRKR)

[Phantom Lord]

They are progressing. Probably not at a rate we would all like but they are progressing. Originally we were supposed to get interim results from the TPIV 200 trial for ovarian in Q1 of next year. When I spoke with Peter he said it might be pushed out to Q2. This was in part to the reduction in their cash position early this year. They had to slow the progression but now that they have received more funding this should pick back up again but could be delayed to Q2. Not a big deal even though we would all like it sooner. This was in regard to the Tapimmune sponsored trial (HERE) which is still enrolling. The combination trial w/ AstraZeneca (HERE) has an estimated completion date of May 2019 so we might see some data before years end.

As for as communication from the company goes there really isn't a reason for them to issue PRs on progress of the trials unless something goes catastrophically wrong or ridiculously good. Most of the updates on the trials come in the conference calls so definitely pay attention to those. Otherwise, we just have to wait for the results.

I have an email out to IR to see if they can give any updates on the trials and will report back if I get any substantial information.